Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;4(4):491-501.
doi: 10.1007/s40121-015-0091-9. Epub 2015 Sep 28.

Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA)

Maren Eggers  1 , Markus Eickmann  2 , Juergen Zorn  3
Affiliations

Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA)

Maren Eggers et al. Infect Dis Ther. 2015 Dec.

Abstract

Introduction: Since the first case of Middle East Respiratory Syndrome coronavirus (MERS-CoV) infection was reported in 2012, the virus has infected more than 1300 individuals in 26 countries, and caused more than 480 deaths. Human-to-human transmission requires close contact, and has typically occurred in the healthcare setting. Improved global awareness, together with improved hygiene practices in healthcare facilities, has been highlighted as key strategies in controlling the spread of MERS-CoV. This study tested the in vitro efficacy of three formulations of povidone iodine (PVP-I: 4% PVP-I skin cleanser, 7.5% PVP-I surgical scrub, and 1% PVP-I gargle/mouthwash) against a reference virus (Modified vaccinia virus Ankara, MVA) and MERS-CoV.

Methods: According to EN14476, a standard suspension test was used to assess virucidal activity against MVA and large volume plating was used for MERS-CoV. All products were tested under clean (0.3 g/L bovine serum albumin, BSA) and dirty conditions (3.0 g/L BSA + 3.0 mL/L erythrocytes), with application times of 15, 30, and 60 s for MVA, and 15 s for MERS-CoV. The products were tested undiluted, 1:10 and 1:100 diluted against MVA, and undiluted against MERS-CoV.

Results: A reduction in virus titer of ≥4 log10 (corresponding to an inactivation of ≥99.99%) was regarded as evidence of virucidal activity. This was achieved versus MVA and MERS-CoV, under both clean and dirty conditions, within 15 s of application of each undiluted PVP-I product.

Conclusion: These data indicate that PVP-I-based hand wash products for potentially contaminated skin, and PVP-I gargle/mouthwash for reduction of viral load in the oral cavity and the oropharynx, may help to support hygiene measures to prevent transmission of MERS-CoV.

Funding: Mundipharma Research GmbH & Co.

Keywords: Enveloped virus; Gargle; Hand hygiene; MERS-CoV; MVA; Middle East respiratory syndrome coronavirus; Modified vaccinia virus Ankara; Mouthwash; Povidone iodine; Virucidal.

PubMed Disclaimer

References

    1. Berry M, Gamieldien J, Fielding BC. Identification of new respiratory viruses in the new millennium. Viruses. 2015;7(3):996–1019. doi: 10.3390/v7030996. - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention. Frequently Asked Questions about SARS. http://www.cdc.gov/sars/about/faq.html. Accessed July 2015.
    1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–1820. doi: 10.1056/NEJMoa1211721. - DOI - PubMed
    1. World Health Organization (WHO). Middle East respiratory syndrome coronavirus (MERS-CoV) Summary of Current Situation, Literature Update and Risk Assessment. 2015. http://apps.who.int/iris/bitstream/10665/179184/2/WHO_MERS_RA_15.1_eng.p.... Accessed July 2015.
    1. World Health Organization (WHO). Emergencies preparedness, response. Summary and risk assessment of current situation in Republic of Korea and China. http://www.who.int/csr/disease/coronavirus_infections/risk-assessment-19.... Accessed July 2015.